Postmarket Surveillance Plans May Be Less Burdensome Under Proposed Rule
This article was originally published in The Gray Sheet
Executive Summary
Medical device manufacturers would be able to satisfy postmarket surveillance orders using secondary data collection methods or literature reviews, provided their proposed method answered the surveillance question posed by FDA, under an Aug. 29 proposed rule.
You may also be interested in...
CDRH Postmarket Surveillance Final Rule To Take Effect July 8
FDA approval need only be obtained for "significant" changes to approved postmarket surveillance (PS) studies, the agency clarifies in a 1June 6 final rule
CDRH Postmarket Surveillance Final Rule To Take Effect July 8
FDA approval need only be obtained for "significant" changes to approved postmarket surveillance (PS) studies, the agency clarifies in a 1June 6 final rule
Postmarket Problems: FDA Struggles To Achieve Manufacturer Compliance
CDRH's cardiovascular review division has faced resistance from PMA sponsors in complying with post-approval study requirements that involve new patient registries, an official from the division reported May 9 at the North American Society of Pacing and Electrophysiology annual meeting